BUY
AbbVie Inc.
They have oncology and immunology drugs, and pay a solid dividend yield. A great toehold in healthcare.
0
BUY
AbbVie Inc.
Likes healthcare, entire sector sold off somewhat in January. Bit of an opportunity. 11x forward PE, pretty decent growth rate. Issues with expiring drug patents, but they'll replace these. One of the premier names in the space. He owns MRK and PFE. Nice yield of 3.9%.
0
SELL
AbbVie Inc.
He used to own, but moved on because Humira coming off patent this year. Lower growth trajectory. Looks great on paper, but you have to get into the weeds to see where it might go, not where it's been.
0
DON'T BUY
AbbVie Inc.
A good pharma, much larger after buying Allergan. They were spun off years ago from another company because major drug, Humira, was a cash cow. Because Humira has become 60-65% of all revenues, AbbVie smartly bought Allergan (Botox). Now, Humira amounts to 45% of revenues, and Humira went off-patent last year. A few big drugs are trying to fill that hole. He owned this before, but feels it's too risky now.
0
BUY
AbbVie Inc.
Better investment than Pfizer. Demand in China will grow. Cancer side of business will continue to grow. Aesthetics business will also grow.
0
BUY
AbbVie Inc.
They report today. She trimmed it earlier this year to take profits. She really likes healthcare--traditionally defensive but also a disruptive/growth space. MRNA has spotlighted how much more can be done in therapeutics. It's a growth and value trade.
0
BUY
AbbVie Inc.
BMY and AbbVie The line is blurred between biotech and pharma. He likes both spaces and both stocks. Aging demographics means more and more drugs. Both are have solid valuations. They pay income but also offer capital appreciation.
0
BUY
AbbVie Inc.
Really likes it. Pays a nearly 4% dividend yield and 8% free cash flow. Has a strong portfolio of drugs. Skyrizi is growing like a weed. Likes it going into earnings.
0
BUY
AbbVie Inc.
He owns it for the dividend, pricing power and it has recreated after several missteps. Definitely holding this.
0
BUY
AbbVie Inc.
Headwind ahead as major product offering facing a patent challenge. Sales are remaining strong with the company regardless. Cosmetics business (Botox) very resilient, even during a recession. Pipeline of new drug development is also looking good. Good time to buy shares. Strong dividend as well.
0
SELL
AbbVie Inc.
Good time to sell the stock. Has sold shares. Doesn't see positive upside for the stock. Numbers of the surface (dividend yield, cash flow yield) look good. Problem is that one of major drugs loses patent next year. Building pipeline of R&D in consumer drugs.
0
BUY
AbbVie Inc.
A great CEO. Pays a 4% yield. He isn't worried about Humira coming off patent, because they have a lot of cash.
0
BUY
AbbVie Inc.
He likes healthcare and likes their 4.1% dividend. It's cheap at 10x earnings. There are concerns about their big drug coming off patent, but management can transition their main drug coming off patent.
0
BUY
AbbVie Inc.
Reported a mix quarter today. Though shares are down today, it's still up 5% YTD. AbbVie re-affirmed guidance. She wouldn't read too much into the quarter.
0
BUY
AbbVie Inc.
Healthcare is his favourite defensive sector. AbbVie needs to provide clear guidance about the erosion curve in Humira, its top drug (that will go off-patent next year). A popular drug going generic isn't necessarily a death sentence for the stock. He thinks management can pull this off. Sales declined only slightly, despite a 40% drop in Humira. Today, they announced a $2.2 billion settlement in opiod litigation (the opiod epidemic) which removes that overhang. It's probably a pretty good buy here.
0
Showing 1 to 15 of 135 entries

AbbVie Inc.(ABBV-N) Rating

Ranking : 5 out of 5

Bullish - Buy Signals / Votes : 34

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 8

Total Signals / Votes : 42

Stockchase rating for AbbVie Inc. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

AbbVie Inc.(ABBV-N) Frequently Asked Questions

What is AbbVie Inc. stock symbol?

AbbVie Inc. is a American stock, trading under the symbol ABBV-N on the New York Stock Exchange (ABBV). It is usually referred to as NYSE:ABBV or ABBV-N

Is AbbVie Inc. a buy or a sell?

In the last year, 42 stock analysts published opinions about ABBV-N. 34 analysts recommended to BUY the stock. 8 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for AbbVie Inc..

Is AbbVie Inc. a good investment or a top pick?

AbbVie Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for AbbVie Inc..

Why is AbbVie Inc. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is AbbVie Inc. worth watching?

42 stock analysts on Stockchase covered AbbVie Inc. In the last year. It is a trending stock that is worth watching.

What is AbbVie Inc. stock price?

On 2023-01-27, AbbVie Inc. (ABBV-N) stock closed at a price of $146.28.